Drug-eluting stents: A comprehensive appraisal

Future Cardiology

Volumn 5, Issue 2, 2009, Pages 141-157

  Butt, Mehmood ^a   Connolly, Derek ^b   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

Coronary artery disease; Paclitaxel eluting stent; Randomized controlled trials; Sirolimus eluting stunt

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PACLITAXEL; PRASUGREL; RAPAMYCIN;

BARE METAL STENT; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SLOW RELEASE FORMULATION; ST SEGMENT ELEVATION; STENT THROMBOSIS; VEIN GRAFT;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; PROSTHESIS DESIGN; TREATMENT OUTCOME;

EID: 66949179083     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.5.2.141     Document Type: Review

References (105)

1. Dotter CT, Judkins MP: Transluminal treatment of arteriosclerotic obstruction: description of a new technique and a preliminary report of its application. Circulation 30, 654-670 (1964).
2. Hurst JW: The first coronary angioplasty as described by Andreas Gruentzig. Am. J. Cardiol. 57, 185-186 (1986).
3. Miller JM, Ohman EM, Moliterno DJ: Restenosis: the clinical issues. In: Textbook of Interventional Cardiology (3rd Edition). Topol Ej (Ed.). WB Saunders, PA, USA, 379-415 (1999).
4. Karthikeyan G, Bhargava B: Prevention of restenosis angioplasty. Curr. Opin. Cardiol. 19, 500-509 (2004).
5. Mueller RL, Sanborn TA: The history of interventional cardiology: cardiac catheterization, angioplasty, and related interventions. Am. Heart J. 129, 146-172 (1995).
6. Fischman DL, Leon MB, Baim DS et al.; for The Stent Restenosis Study Investigators: A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med. 331, 496-501 (1994).
7. Serruys PW, de Jaegere P, Kiemeneij F et al.; for The Benestent Study Group: a comparison of balloon-expandablestent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med. 331, 489-495 (1994).
8. Schomig A, Neumann FJ, Kastrati A et al.: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. 334, 1084-1089 (1996).
9. Yokol H, Kimura T, Nakagawa Y, Nosaka H, Nobuyoshi M: Long-term clinical and quantitative angiographic follow-up after the Palmaz-Schatz stent restenosis [abstract]. J. Am. Coll. Cardiol. 27, 224A (1996).
10. Raizner AE, Oesterle SN, Waksman R et al.: Inhibition of restenosis with β-emitting radiotherapy: report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation 102, 951-958 (2000).
11. Htay T, Liu MW. Drug-eluting stent: a review and update. Vasc. Health Risk Manag. 1, 263-276 (2005).
12. Liu MW, Roubin GS, King SB III: Restenosis following coronary angioplasty potential biological determinants and role of intimal hyperplasia. Circulation 79, 1374-1387 (1989).
13. Virmani R, Farb A: Pathology of in-stent restenosis. Curr. Opin. Lipidol. 10, 499-506 (1999).
14. Hwang CW, Wu D, Edelman ER: Physiological transport forces govern drug distribution for stent-based delivery. Circulation 104, 600-605 (2001).
15. Takebayashi H, Mintz GS, Carlier SG et al.: Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimuseluting stent implantation. Circulation 110, 3430-3434 (2094).
16. Sousa JE, Costa MA, Sousa AG et al.: Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 107, 381-383 (2003).
17. Tanabe K, Regar E, Lee CH, Hoye A, van der Giessen WJ, Serruys PW: Local drug delivery using coated sterits: new developments and future perspectives. Curr. Pharm. Des. 10, 357-367 (2004).
18. Aoki J, Serruys PW, van Beusekom H et al.: Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J. Am. Coll. Cardiol. 45, 1574-1579 (2005).
19. Morice MC, Serruys PW, Sousa JE et al.; for the RAVEL study group: A randomized comparison ofa sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346, 1773-1780 (2002).
20. Moses JW, Leon MB, Popma JJ et al.; SIRIUS investigatots: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349, 1315-1323 (2003).
21. Schofer J, Schluter M, Gershlick AH et al.; E-SIRIUS investigators: Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362, 1093-1099 (2003).
22. Schampaert E, Cohen EA, Schluter M et al.; C-SIRIUS investigators: The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions - in small native coronary arteries (C-SIRIUS). J. Am. Coll. Cardiol. 43, 1110-1115 (2004).
23. Ardissino D, Cavallini C, Bramucci E et al.; SES-SMART investigators: Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 292, 2727-2734 (2004).
24. Pache J, Dibra A, Mehilli J, Dirschinger J, Schomig A, Kastrati A: Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur. Heart J. 26, 1262-1268 (2005).
25. Ortolani P, Mafzocchi A, Marrozzini C et al.: Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. Catheter Cardiovasc. Interv. 69, 790-798 (2007).
26. Kelbaek H, Thuesen L, Helqvist S et al.: SCANDSTENT investigators: The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. J. Am. Coll. Cardiol. 47, 449-455 (2006).
27. Suttorp MJ, Lawman GJ, Rahel BM et al.: Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 114, 921-928 (2006).
28. Waugh J, Wagstaff AJ: The paclitaxel (TAXUS)-eluting stent: a review of its use in the management of de novo coronary artery lesions. Am. J. Cardiovasc. Drugs 4, 257-268 (2004).
29. Grube E, Silber S, Hauptmann KE et al.: TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107, 38-42 (2003).
30. Colombo A, Drzewiecki J, Banning A et al.: TAXUS II study group: Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108, 788-794 (2003).
31. Stone GW, Ellis SG, Cox DA et al.: TAXUS-IV investigators: One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109, 1942-1947 (2004).
32. Stone GW, Ellis SG, Cannon L et al.: TAXUS V investigators: Comparison of a polymer-based paclitaxel eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294, 1215-1223 (2005).
33. Dawkins KD, Grube E, Guaglium C et al.: TAXUS VI investigatiors: Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 112, 3306-3313 (2005).
34. Erglis A, Narbute I, Kumsars I et al.: A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. J. Am. Coll. Cardiol. 50, 491-497 (2007).
35. Kastrati A, Mehilli J, von Beckerath N et al.: ISAR-DESIRE study investigators: Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293, 165-171 (2005).
36. Goy JJ, Stauffer JC, Siegenthaler M, Benoit A, Seydoux C: A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology. The TAXi trial. J. Am. Coll. Cardiol. 45, 308-311 (2005).
37. Windecker S, Remondino A, Eberli FR et al.: Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N. Engl. J. Med. 353, 653-662 (2005).
38. Galløe AM, Thuesen L, Kelbaek H et al.: SORT OUT II investigators: Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA 299, 409-416 (2008).
39. Morice MC, Colombo A, Meier B et al.: REALITY trial investigators: Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 295, 895-904 (2006).
40. Stone GW, Brodie BR, Griffin JJ et al.: Clinical and angiographic follow-up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation 99, 1548-1554 (1999).
41. Spaulding C, Henry P, Teiger E et al.: TYPHOON investigators: Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N. Engl. J. Med. 355, 1093-104 (2006).
42. Menichelli M, Parma A, Pucci E et al.: Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J. Am. Coll. Cardiol. 49, 1924-1930 (2007).
43. van der Hoeven RL, Liem SS, Jukema JW, et al.: Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12 month clinical outcome results from the MISSON! Intervention Study. J. Am. Coll: Cardiol. 51, 618-626 (2008).
44. Laarman GJ, Suttorp MJ, Dirksen MT et al.: Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N. Engl. J. Med. 355, 1105-1113 (2006).
45. Hofma SH, Ong AT, Aoki J et al.: One year clinical follow up of paclitaxel eluting stents for acute myocardial infarction compared with sirolimus eluting stents. Heart 91, 1176-1180 (2005).
46. Lee JH, Kim HS, Lee SW et al.: Prospective randomized comparison of sirolimus-versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: pROSIT trial. Catheter Cardiovasc. Interv. 72, 25-32 (2008).
47. Kastrati A, Spaulding C, Laarman GJ et al.: Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur. Heart J. 28, 2706-2713 (2007).
48. Nakazawa G, Finn AV, Joner M et al.: Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 118, 1138-1145 (2008).
49. Steg PG, Fox KA, Eagle KA et al.: Global Registry of Acute Coronary Events (GRACE) investigators: Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur. Heart J. 30, 321-329 (2009).
50. Cutlip DE, Chhabra AG, Bairn DS et al.: Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation 110, 1226-1230 (2004).
51. Stone KE, Chiquette E, Chilton RJ: Diabetic endovascular disease: role ofcoronary artery revascularization. Am. J. Cardiol. 99, 105B-112B (2007).
52. Iakovou I, Schmidt T, Bonizzoni E et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293, 2126-2130 (2005).
53. Lee TT, Feinberg L, Baim DS et al.: Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials). Am. J. Cardiol. 98, 718-721 (2006).
54. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW: A pooled analysis of data comparing sirolimus-eluting stents with baremetal stents. N. Engl. J. Med. 356, 989-997 (2007).
55. Sabate M, Jimenez-Quevedo P, Angiolillo DJ et al.; DIABETES investigators: Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 112, 2175-2183 (2005).
56. Baumgart D, Klauss V, Baer F et al.; SCORPIUS study investigators. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J. Am. Coll. Cardiol. 50, 1627-1634 (2007).
57. Ortolani P, Balducelli M, Marzaroli P et al.: Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry. [i Circulation 117, 923-930 (2008).
58. Dibra A, Kastrati A, Mehilli J et al.; ISAR-DIABETES study investigators: paclitaxel-eluting or sirolimits-eluting stents to prevent restenosis in diabetic patients. N. Engl. J. Med. 353, 663-670 (2005).
59. Lee SW, Park SW, Kim YH et al.: A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus. J. Am. Coll. Cardiol. 52, 727-733 (2008).
60. Alexander JH, Halley G, Harrington RA et al.; PREVENT IV investigators: Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 294, 2446-2454 (2005).
61. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR:. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1388 patients during 25 years. J. Am. Coll. Cardiol. 28, 616-626 (1996).
62. Weintraub WS, Jones EL, Morris DC, King SB 3rd, Guyton RA, Craver JM: Outcome of reoperative coronary bypass surgery versus coronary angioplasty after previous bypass surgery. Circulation 95, 868-877 (1997).
63. Silber S, Albertsson P, Avilés FF et al.; Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology: Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur. Heart J. 26, 804-847 (2005).
64. Agostoni P, Vermeersch P, Semeraro O et al.: Intravascular ultrasound comparison of sirolimus-eluting stent versus bare, metal stent implantation in diseased saphenous vein grafts (from the RRISC [Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent] trial). Am. J. Cardiol. 100, 52-58 (2007).
65. Vermeersch P, Agostoni P, Verheye S et al.: Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC trial. J. Am. Coll. Cardiol. 48, 2423-2431 (2006).
66. Hoffmann R, Pohl T, Köster R, Blindt R, Boeckstegers P, Heitzer T: Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. Heart 93, 331-334 (2007).
67. Chu WW, Kuchulakanti PK, Wang B et al.: Efficacy of sirolimus-eluting stents as compared with paclitaxel-eluting stents for saphenous vein graft intervention. J. Interv. Cardiol. 19, 121-125 (2006).
68. Gioia G, Benassi A, Mohendra R, Chowdhury K, Masood I, Matthai W: Lack of clinical long-term benefit with the use of a drug eluting stent compared with use of a bare metal stent in saphenous vein grafts. Catheter Cardiovasc. Interv. 72, 13-20 (2008).
69. Okabe T, Lindsay J, Buch AN et al.: Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts. Am. J. Cardiol. 102, 530-534 (2008).
70. Kereiakes DJ, Choo JK, Young JJ, Broderick TM: Thrombosis and drug eluting stents: a critical appraisal. Rev. Cardiovasc. Med. 5, 9-15 (2004).
71. Finn AV, Joner M, Nakazawa G et al.: Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115, 2435-2441 (2007).
72. Joner M, Nakazawa G, Finn AV et al.: Endothelial cell recovery between comparator polymer-based drug-eluting stents. J. Am. Coll. Cardiol. 52: 333-342 (2008).
73. Nakazawa G, Finn AV, Kolodgie FD, Virmani R: A review of current devices and a look at new technology: drug-eluting stents. Expert Rev. Med. Devices 6, 33-42 (2009).
74. Kumbhani DJ, Bavry AA, Kamdar AR, Helton TJ, Bhatt DL: The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials. Am. Heart J. 2008; 155: 640-647
75. Yan BP, Duffy SJ, Clark DJ et al.; Melbourne Interventional Group: Rates of stent thrombosis in bare-metal versus drug-eluting stents (from large Australian multicenter registry). Am. J. Cardiol. 101, 1716-1722 (2008).
76. Kirtane AJ, Ellis SG, Dawkins KD et al.: Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J. Am. Coll. Cardiol. 51, 708-715 (2008).
77. Stone GW, Ellis SG, Colombo A et al.: Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation 115, 2842-2847 (2007).
78. Togni M, Windecker S, Cocchia R et al.: Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol. 46, 231-236 (2005).
79. Hofma SH, van der Giessen WJ, van Dalen BM et al.: Indication of long-term endothelial dysfunction after sirolimus eluting stent implantation. Eur. Heart J. 27, 166-170 (2006).
80. Pasceri V, Patti G, Speciale G, Pristipino C, Richichi G, Di Sciascio G: Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am. Heart J. 153, 749-754 (2007).
81. Wenaweser P, Daemen J, Zwahlen M et al.: Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J. Am. Coll. Cardiol. 52, 1134-1140 (2008).
82. Kirtane AJ, Ellis SG, Dawkins KD et al.: Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J. Am. Coll. Cardiol. 51, 708-715 (2008).
83. Schömig A, Dibra A, Windecker S et al.: A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J. Am. Coll. Cardiol. 50, 1373-1380 (2007).
84. Hoye A, Iakovou I, Ge L et al.: Long-term outcomes after stenting of bifurcation lesions with the 'crush' technique: predictors of an adverse outcome. J. Am. Coll. Cardiol. 47, 1949-1958 (2006).
85. Holmes DR Jr, Kereiakes DJ, Laskey WK et al.: Thrombosis and drug-elutmig stents: an objective appraisal. J. Am. Coll. Cardiol. 50, 109-118 (2007).
86. Makaryus JN, Volfson A, Azer V, Bogachuk E, Lee A: Acute stent thrombosis in the setting of Cocaine abuse following percutaneous coronary intervention. J. Interv. Cardiol. (2008) (Epub ahead of print).
87. Mintz GS, Weissman NJ: Intravascular ultrasound in the drug-eluting stent era. J. Am. Coll. Cardiol. 48, 421-429 (2006).
88. Karvouni E, Korovesis S, Katritsis DG: Very late thrombosis after implantation of sirolimus eluting stent. Heart 91, E45 (2005).
89. Grines CL, Bonow RO, Casey DE Jr et al.; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians: Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J. Am. Coll. Cardiol. 49, 734-739 (2007).
90. Banerjee S, Varghese C, Samuel J et al.: Comparison of the impact of short (<1 year) and long-term (≥ year) clopidogrel use following percutaneous coronary intervention on mortality. Am. J. Cardiol. 102, 1159-1162 (2008).
91. Lee S-W, Park S-W, Hong M-K et al.: Triple versus dual antiplatelet therapy after coronary stenting, impact on stent thrombosis. J. Am. Coll. Cardiol. 46, 1833-1837 (2005).
92. Wiviott SD, Braunwald E, McCabe CH et al.; TRITON-TIMI 38 investigators: Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 371, 1353-1363 (2008).
93. Meredith IT, Ormiston J, Whitbourn R et al.: First-in-human study of the endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I trial. EuroIntervention 1, 157-164 (2005).
94. Fajadet J, Wijns W, Laarman GJ et al.; ENDEAVOR II investigators: Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114, 798-806 (2006).
95. Kandzari DE, Leon MB, Popma JJ et al.; ENDEAVOR III investigators: Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J. Am. Coll. Cardiol. 48, 2440-2447 (2006).
96. Grube E, Sonoda S, Ikeno F et al.: Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 109, 2168-2171 (2004).
97. Stone GW, Midei M, Newman W et al.; SPIRIT III investigators: Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299, 1903-1913 (2008).
98. Han YL, Wang SL, Jing QM et al.: Midterm outcomes of prospective, randomized, single-center study of the Janus tacrolimus-eluting stent for treatment of native coronary artery lesions. Chin. Med. J. (Engl.) 120, 552-556 (2007).
99. Morice MC, Bestehorn HP, Carrié D et al.; Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial. EuroIntervention 2, 45-52 (2006).
100. Co M, Tay E, Lee CH et al.: Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: intermediate- to long-term clinical follow-up. Am. Heart J. 155, 128-132 (2008).
101. Petronio AS, De Carlo M, Branchitta G et al.: Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study. J. Am. Coll. Cardiol. 49, 539-546 (2007).
102. Mahmud E, Bromberg-Marin G, Palakodeti V, Ang L, Creanga D, Demaria AN: Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J. Am. Coll. Cardiol. 51, 2385-2395 (2008).
103. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE: Stent thrombosis in randomized clinical trials of drug-eluting stents. N. Engl. J. Med. 356, 1020-1029 (2007).
104. Schampaert E, Moses JW, Schofer J et al.; SIRIUS, E- and C-SIRIUS investigators: Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am. J. Cardiol. 98, 36-41 (2006).
105. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL: What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention: a meta-analysis. J. Am. Coll. Cardiol. 45, 941-946 (2005).